Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine if the timing of administration of indomethacin affects the primary outcome of post-ERCP pancreatitis (PEP). Patients undergoing ERCP will be randomly assigned to receive pre or post-procedure rectal indomethacin to prevent the occurrence of PEP.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alberta
• Treatments: Indomethacin

Criteria

Inclusion Criteria:

• All patients referred for ERCP at the University of Alberta

• Age greater than 18 years

• Ability to provide written informed consent

Exclusion Criteria:

• Acute pancreatitis

• Active peptic ulcer disease

• Rectal disease

• Aspirin-induced asthma

• Nonsteroidal anti-inflammatory drug (NSAIDs) induced hypersensitivity

• Pregnancy

• Breast feeding

• Creatinine clearance < 30 ml/min